sorafenib has been researched along with Dermatoses in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (37.14) | 29.6817 |
| 2010's | 19 (54.29) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas, MN; Kichenadasse, G; Tan, WS | 1 |
| Chen, D; Han, G; Li, L; Liu, L; Peng, K; Wang, E; Wang, M | 1 |
| Cho, SB; Hong, YM; Hwang, SY; Jang, BK; Jang, ES; Jang, JY; Jung, YK; Kim, DY; Kim, HJ; Kim, JH; Kim, MY; Lee, HW; Lee, JH; Lee, YS; Seo, YS; Yim, HJ; Yoon, KT | 1 |
| Gómez Zubiaur, A; Medina Montalvo, S; Vega Díez, D | 1 |
| Lee, WJ; Tam, HP | 1 |
| Cury-Martins, J; Domingues, RB; Macarenco, R; Sanches, JA; Sato-Sano, M; Vasconcelos, R | 1 |
| Beasley, JM; Brinster, NK; Lederhandler, M; Nagler, AR | 1 |
| Bruix, J; da Fonseca, L; Díaz-González, Á; Forner, A; Iserte, G; LLarch, N; Reig, M; Ríos, J; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ | 1 |
| Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z | 1 |
| Bulai Livideanu, C; Christol, C; Hautier-Mazeereuw, J; Lamant, L; Paul, C; Pauwels, C; Peron, JM; Severino-Freire, M; Sibaud, V; Tournier, E | 1 |
| Baker, SD; Chen, T; Du, G; Gibson, AA; Hu, S; Inaba, H; Maitland, ML; Mascara, GP; Ong, SS; Orwick, SJ; Sparreboom, A; Vasilyeva, A; Vogel, P; Zimmerman, EI | 1 |
| Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I | 1 |
| Escudier, B; Mateus, C; Robert, C; Spatz, A; Wechsler, J | 1 |
| Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
| Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC | 1 |
| Kong, HH; Turner, ML | 1 |
| Chevreau, C; Delord, JP; Sibaud, V | 1 |
| Dupre-Goetghebeur, D; Jantzem, H; Merrer, J; Spindler, P | 1 |
| Bellmunt, J; Eisen, T; Fishman, M; Quinn, D | 1 |
| Ausoni, G; Bayer, AJ; Bellesi, S; Chiusolo, P; Giammarco, S; Laurenti, L; Leone, G; Mario, B; Metafuni, E; Sica, S; Sorà, F; Zini, G | 1 |
| Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L | 1 |
| Ma, L; Wang, Y; Wu, Z; Zhang, L; Zhou, Q | 1 |
| Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M | 1 |
| Hong, SH; Jeon, EK; Jeong, HK; Ko, YH; Lee, SL; Roh, SY; Shin, OR; Won, HS | 1 |
| Aiello, RA; Alì, M; Caruso, M; La Rocca, R; Licciardello, P; Sanò, MV; Scandurra, G; Taibi, E; Todaro, FM | 1 |
| Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E | 1 |
| Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W | 1 |
| Armand, JP; Boige, V; Escudier, B; Le Cesne, A; Le Chevalier, T; Lhomme, C; Malka, D; Pautier, P; Robert, C; Soria, JC; Spatz, A; Wechsler, J | 1 |
| Azad, NS; Cowen, EW; Dahut, W; Gutierrez, M; Kong, HH; Turner, ML | 1 |
| Robert, C | 1 |
| Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC | 1 |
| Chu, D; Fillos, T; Lacouture, ME; Wu, S | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
9 review(s) available for sorafenib and Dermatoses
| Article | Year |
|---|---|
Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Retrospective Studies; Skin Diseases; Sorafenib; Survival Rate | 2019 |
Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Humans; Hypertension; Hypokinesia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib; Survival | 2013 |
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib | 2009 |
Experience with sorafenib and adverse event management.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypertension; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib | 2011 |
Meta-analysis of dermatological toxicities associated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Skin Diseases; Sorafenib | 2011 |
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Topics: Antibodies, Blocking; Antineoplastic Agents; Benzamides; Benzenesulfonates; ErbB Receptors; Hair Diseases; Humans; Imatinib Mesylate; Nail Diseases; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Skin Diseases; Sorafenib | 2005 |
[Cutaneous side effects of antiangiogenic agents].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Pyridines; Pyrroles; Skin Diseases; Sorafenib; Sunitinib | 2007 |
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions; Foot; Hand; Humans; Incidence; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Risk Factors; Skin; Skin Diseases; Sorafenib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
3 trial(s) available for sorafenib and Dermatoses
| Article | Year |
|---|---|
Effect of urea cream on sorafenib-associated hand-foot skin reaction in patients with hepatocellular carcinoma: A multicenter, randomised, double-blind controlled study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Quality of Life; Skin; Skin Cream; Skin Diseases; Sorafenib; Urea | 2020 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
23 other study(ies) available for sorafenib and Dermatoses
| Article | Year |
|---|---|
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib | 2021 |
As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization plus Sorafenib.
Topics: Adult; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Female; Humans; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome | 2019 |
Reactive perforating collagenosis: a rare side effect associated with sorafenib.
Topics: Carcinoma, Hepatocellular; Collagen Diseases; Humans; Liver Neoplasms; Skin Diseases; Sorafenib | 2020 |
Painful skin reaction.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Emergency Service, Hospital; Hand-Foot Syndrome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib | 2017 |
Perforating dermatosis associated with multikinase inhibitors: report of two cases, including one associated with lenvatinib.
Topics: Abdomen; Aged; Carcinoma; Carcinoma, Hepatocellular; Folliculitis; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Skin Diseases; Sorafenib; Thigh; Thyroid Neoplasms | 2018 |
Unusual eruption in association with sorafenib: a case of acquired perforating dermatosis, reactive perforating collagenosis type.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Collagen Diseases; HIV Infections; Humans; Liver Neoplasms; Male; Skin Diseases; Sorafenib | 2018 |
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Skin Diseases; Sorafenib | 2014 |
Acquired perforating dermatosis associated with sorafenib therapy.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Skin; Skin Diseases; Sorafenib | 2016 |
Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.
Topics: Animals; Cell Death; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Keratinocytes; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Niacinamide; Nuclear Receptor Subfamily 2, Group C, Member 2; Organic Anion Transporters; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Skin; Skin Diseases; Sorafenib; Transfection | 2016 |
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib | 2009 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult | 2009 |
Array of cutaneous adverse effects associated with sorafenib.
Topics: Benzenesulfonates; Biopsy, Needle; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunohistochemistry; Incidence; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Risk Assessment; Skin Diseases; Sorafenib | 2009 |
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Skin Tests; Sorafenib | 2009 |
[Sorafenib-induced multiple eruptive keratoacanthomas].
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunosuppressive Agents; Keratoacanthoma; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Sunlight | 2009 |
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2011 |
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Disease Progression; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Survival Rate | 2010 |
Pancreatic endocrine tumors: a report on a patient treated with sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Humans; Liver Neoplasms; Male; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Tomography, X-Ray Computed | 2011 |
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib | 2012 |
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome; Vomiting | 2013 |
Keratoacanthomas associated with sorafenib therapy.
Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanthoma; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neck; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib | 2007 |
Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib | 2007 |